1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsInnovative Molecular Analysis Technologies (IMAT) Program is sponsored by National Institutes of Health (NIH). Supports the development of innovative technologies for molecular analysis, including AI systems for medical applications.
Get alerted about grants like this
Save a search for “National Institutes of Health (NIH)” or related topics and get emailed when new opportunities appear.
Search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
About | Innovative Molecular Analysis Technologies (IMAT) Program - NCI Innovative Molecular Analysis Technologies (IMAT) Program Read the RFAs for novel technology development projects. Early-stage development of technologies: R61 Advanced development of technologies: R33 IMAT uses the R33 grant mechanism to support advanced development and validation of emerging technologies.
This mechanism is suitable for technologies that have preliminary data to demonstrate that major feasibility gaps have been overcome, but still require further development and rigorous validation for broad adoption by the research community.
Adoption of emerging technologies by research community: Competitive Revisions Through the competitive revision mechanism , currently funded NCI grantees with an R01, U01, or P50 award can apply for additional funds to expand upon the original research question(s) or otherwise accelerate progress for the parent study by incorporating a new technical approach developed through support from the IMAT program.
The PI of the R01, U01, or P50 who is receiving the revision award cannot be the IMAT-supported investigator; these projects are meant to provide independent validation of the emerging technologies and spur collaborations between tool developers and end users. History of the IMAT Program Technical innovation can improve and transform our ability to understand, prevent, diagnose, and treat cancer.
NCI established the IMAT program in 1998 to focus support on the development of innovative technologies that meet the specific needs of cancer researchers and clinicians and offer the potential to accelerate progress in the fight against cancer. The program promotes interdisciplinary research that brings diverse expertise to tackle persistent challenges in cancer research that are most in need of technical innovation.
Read about IMAT projects focused on the development of novel technologies for cancer research. By taking risks on early-stage technology development projects that have the potential to transform cancer research, IMAT has contributed to the development of many of the most widely used technologies across the cancer research and clinical communities.
MuDPIT , Rolling Circle Amplification , ROMA , Illumina bead platforms , and ICAT technologies were all supported by IMAT grants in the late 1990s. In the 2000s, IMAT supported development of activity-based protein profiling , PROTACS and numerous liquid biopsy , imaging mass spectrometry , single-cell analysis , and spatial -omic methods that are leading their fields today.
To encourage the adoption of emerging technologies by the research community, the IMAT program began soliciting proposals for competitive revisions to ongoing NCI research projects in 2018. This component of the program incentivizes independent validation of IMAT-supported technologies by early adopters of new technologies.
As new challenges emerge for cancer researchers and clinicians, the need for a technology development pipeline encompassing inception and initiation through dissemination and commercialization endures. The IMAT program serves a unique role at NCI in the early stages of this pipeline. The program is regularly evaluated by panels of external experts and subsequently evolves to meet the needs of the research community.
A summary of the findings from these evaluations can be found in CSSI’s Program Evaluation Reports page. Every year since 1999, all researchers with an active IMAT project have gathered for the annual IMAT PI meeting to share progress on their developing technologies and form collaborations. Information about these PI meetings going back to the inaugural meeting in 1999 can be found on CSSI’s Past Events page.
Dr. Kelly Crotty ( kelly. crotty@nih. gov ) Center for Strategic Scientific Initiatives Dr. Tony Dickherber ( dickherberaj@mail.
nih. gov ) Division of Cancer Biology Dr. Steven Becker ( steven. becker@nih.
gov ) Dr. Hannah Dueck ( hannah. dueck@nih. gov ) Dr. Cindy Kyi ( cindy.
kyi@nih. gov ) Division of Cancer Treatment and Diagnosis Diagnostic Biomarkers and Technology Dr. Asif Rizwan ( asif. rizwan@nih.
gov ) Dr. Jung Byun ( jung. byun@nih. gov ) Biorepositories and Biospecimen Research Dr. Ping Guan ( ping.
guan@nih. gov ) Dr. Lokesh Agrawal ( lokesh. agrawal@nih.
gov ) Dr. Yisong Wang ( yisong. wang@nih. gov ) Division of Cancer Prevention Dr. Vignesh Gunasekharan ( vignesh.
gunasekharan@nih. gov ) Dr. Nick Hodges ( nick. hodges@nih.
gov ) Division of Cancer Control and Population Sciences Dr. Stefanie Nelson ( stefanie. nelson@nih. gov )
Based on current listing details, eligibility includes: Nonprofits, for-profits, and small businesses in the U. S. Applicants should confirm final requirements in the official notice before submission.
Current published award information indicates Varies Always verify allowable costs, matching requirements, and funding caps directly in the sponsor documentation.
The current target date is rolling deadlines or periodic funding windows. Build your timeline backwards from this date to cover registrations, approvals, attachments, and final submission checks.
Federal grant success rates typically range from 10-30%, varying by agency and program. Build a strong proposal with clear objectives, measurable outcomes, and a well-justified budget to improve your chances.
Requirements vary by sponsor, but typically include a project narrative, budget justification, organizational capability statement, and key personnel CVs. Check the official notice for the complete list of required attachments.
Yes — AI tools like Granted can help research funders, draft proposal sections, and check compliance. However, always review and customize AI-generated content to reflect your organization's unique strengths and the specific requirements of the solicitation.
Review timelines vary by funder. Federal agencies typically take 3-6 months from submission to award notification. Foundation grants may be faster, often 1-3 months. Check the program's timeline in the official solicitation for specific dates.
Many federal programs offer multi-year funding or allow competitive renewals. Check the official solicitation for continuation and renewal policies. Non-competing continuation applications are common for multi-year awards.
NIH NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00) is a grant from the National Institutes of Health (NIH) / National Cancer Institute (NCI) that funds early-stage postdoctoral researchers in cancer-related fields to transition to independent research careers. The award provides a mentored phase (K99) followed by an independent phase (R00), supporting investigators who do not require an extended period of supervised training beyond their doctoral degrees. Eligible applicants must hold a research or clinical doctoral degree and be postdoctoral fellows who have not yet established independent research careers. The March 11, 2026 due date applies; award amounts vary by project.
NIH R25 Summer Research Education Experience Program is a grant from the National Institutes of Health (NIH) that funds universities and institutions of higher education to provide summer research experiences in environmental health sciences to high school students, college undergraduates, and science teachers. Administered through the National Institute of Environmental Health Sciences (NIEHS), the program aims to attract young people to scientific careers and help teachers communicate about the scientific process more effectively. Eligible applicants are U.S. institutions eligible for NIH grants. The application deadline was March 17, 2026.
-Purpose. This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to develop, standardize, and validate new and innovative assays, integrated strategies, or batteries of assays that determine or predict specific organ toxicities (e.g., ocular, dermal, hematotoxicity, cardiotoxicity, gastrointestinal toxicity, hepatotoxicity, nephrotoxicity, ototoxicity, olfactory loss, bladder toxicity, neurotoxicity, pulmonary toxicity, endocrine toxicity, and pancreatic beta cell toxicity), resulting from both acute and chronic exposures to various chemicals, environmental pollutants, biologics and therapeutic molecules or drugs. In addition, this FOA encourages the development, standardization, and validation of new models of arthritis, convulsion, infection and shock. New approaches for high throughput toxicity screening that involves the use of molecular endpoints, computer modeling, proteomics, genomics and epigenomics and the development of virtual tissues are also encouraged as are development of 3-dimensional organ models for toxicity evaluation. -Mechanism of Support. This FOA will utilize the SBIR (R43/R44) grant mechanisms for Phase I, Phase II, and Fast-Track applications and runs in parallel with a FOA of identical scientific scope, PA-09-007, which encourages applications under the Small Business Technology Transfer (STTR) (R41/R42) grant mechanisms. Funding Opportunity Number: PA-09-006. Assistance Listing: 93.113,93.173,93.361,93.389,93.837,93.846,93.847,93.848,93.849,93.859,93.867. Funding Instrument: G. Category: ED,ENV,FN,HL.
Purpose. This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), National Institutes of Health (NIH), invites Small Business Innovation Research (SBIR) cooperative agreement applications from small business concerns (SBCs) that propose to develop new, or to improve existing application(s) of nanotechnology-based therapeutics or/and in vivo diagnostics. This FOA will specifically support pre-clinical optimization and testing of these cancer-relevant nanotechnology applications against the intended cancer type. The proposed projects must be milestone-driven and must be clearly directed toward development of an ultimate commercial product. The outcomes are expected to advance the discovery and pre-clinical optimization phase so that an Investigational New Drug (IND) or Investigational Device Exemptions (IDE) application could be submitted to the Food and Drug Administration (FDA) by the end or shortly after completion of the Phase II project period. To facilitate these steps, the NCI will assist the awardees in various ways, including the support through the NCI-sponsored Nanotechnology Characterization Laboratory. This FOA will NOT support basic research projects, studies on disease mechanisms, and clinical trials. Mechanism of Support. This FOA will utilize the SBIR (U43/U44) cooperative agreement mechanisms for Phase I and Phase II applications. Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received. Funding Opportunity Number: PAR-10-286. Assistance Listing: 93.393,93.394,93.395,93.396. Funding Instrument: CA. Category: ED,HL. Award Amount: Up to $150K per award.
This Funding Opportunity Announcement (FOA) invites Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) for funding to perform research leading to the development of innovative technologies that may advance progress for early detection and assessment of individuals at risk and for early diagnosis, prognosis and follow-up of type 1 diabetes (T1D). Funding Opportunity Number: RFA-DK-15-024. Assistance Listing: 93.847. Funding Instrument: G. Category: FN,HL. Award Amount: $2M total program funding.